Maxillary squamous cell carcinoma (MSCC) represents a relatively uncommon subset of head and neck cancers; however, its aggressive nature and propensity for early cervical lymph node involvement ...

Schematic representation depicts the mechanism by which the ENO2-derived oncometabolite PEP directly binds to HDAC1 and thereby promotes H3K18la, which promotes macrophage polarization and leads to ...

A recent study published in Engineering has shed new light on the mechanisms underlying the metastasis of head and neck squamous cell carcinoma (HNSCC). The research identified enolase 2 (ENO2), a ...

Keytruda and Efti combination therapy achieved a median overall survival of 17.6 months in head and neck squamous cell carcinoma with PD-L1 CPS less than one. The combination therapy demonstrated a ...

Bicara Therapeutics has unveiled updated data for its bifunctional antibody paired with Keytruda in head and neck squamous cell carcinoma (HNSCC), including a first look at overall survival (OS) data ...

CRB-701 targets Nectin-4, delivering chemotherapy directly to cancer cells, minimizing damage to healthy tissue. The FDA's fast track designation aims to expedite CRB-701's development for HNSCC and ...